ARWRArrowhead Pharmaceuticals Inc
−15.3% today · +25.5% over a year
1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 17% of the instruments we score
Priced higher than most peers. No dividend.
Arrowhead Pharmaceuticals Inc (ARWR) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €6.2B. Over the past 12 months the price changed by +25.5%, with an annualised volatility of 62% and a largest fall of 45%. Hard red flags in our rules-based screen: Financial distress.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 338)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Betaweighs on the score · better than 5% of peers
- Accrualssupports the score · better than 86% of peers
- Change in cash flow / assets (5 y)supports the score · better than 91% of peers
Red flags and notes
- Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
- Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
- Caution. Share count growing 3–10 % a year over three years. More in the glossary → Share count growing 3–10 % a year over three years.
- Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/B
- 14.9
- P/S
- 10.4
- Free-cash-flow yield
- −1.1%
- Market cap (EUR)
- €6.2B
Profitability and debt
- Return on equity
- −64.8%
- Return on invested capital
- −23.7%
Dividends
- Dividend yield
- 0.00%
- Years without a lower dividend
- 0
Returns and risk
- 1 day
- −15.3%
- 1 month
- −21.5%
- 1 year
- +25.5%
- Volatility, 1 yr
- 62.0%
- Max drawdown, 1 yr
- −45.0%
- Beta
- 1.77
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| CHEChemed Corp | 10/10 | 0.5% | 24.5% |
|---|---|---|---|
| AXSMAxsome Therapeutics Inc | 1/10 | 0.0% | −3.0% |
| ORKAOruka Therapeutics Inc. | 2/10 | 0.0% | 276.8% |
| KODKodiak Sciences Inc | 1/10 | 0.0% | 507.5% |
| CGONCG Oncology Inc. | 2/10 | 0.0% | 88.4% |
| IMVTImmunovant Inc. | —/10 | 0.0% | 50.5% |
| LNTHLantheus Holdings Inc | 10/10 | 0.0% | 97.8% |
| CAICaris Life Sciences Inc. | 3/10 | 0.0% | −0.2% |
News and filings
- ARROWHEAD PHARMACEUTICALS, INC.: 8-K — Material agreement; new financial obligation
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 4 Nov 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 1 entry
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | 1/10 | 1 · — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.